Sonelokimab. Interleukin-17A and -F nanobody. Treatment of moderate to severe psoriasis. Treatment of hidradenitis suppurativa.

Yiqiu Yao; Astrid-Helene Ravn Jørgensen; Valdemar Wendelboe  Nielsen; Alexander Egeberg; Jacob Pontoppidan  Thyssen; Simon Francis Thomsen

Sonelokimab. Interleukin-17A and -F nanobody. Treatment of moderate to severe psoriasis. Treatment of hidradenitis suppurativa.

Yiqiu Yao, Astrid-Helene Ravn Jørgensen , Valdemar Wendelboe Nielsen, Alexander Egeberg, Jacob Pontoppidan Thyssen, Simon Francis Thomsen

Dermatology, Department of

Original language	English
Journal	Drugs of the Future
Volume	47
Issue number	8
Pages (from-to)	567-573
ISSN	0377-8282
Publication status	Published - 2022

Cite this

@article{c7d05ec844e445c68460726940ea1157,

title = "Sonelokimab. Interleukin-17A and -F nanobody. Treatment of moderate to severe psoriasis. Treatment of hidradenitis suppurativa.",

author = "Yiqiu Yao and J{\o}rgensen, {Astrid-Helene Ravn} and Nielsen, {Valdemar Wendelboe} and Alexander Egeberg and Thyssen, {Jacob Pontoppidan} and Thomsen, {Simon Francis}",

year = "2022",

language = "English",

volume = "47",

pages = "567--573",

journal = "Drugs of the Future",

issn = "0377-8282",

publisher = "Prous Science",

number = "8",

}

TY - JOUR

T1 - Sonelokimab. Interleukin-17A and -F nanobody. Treatment of moderate to severe psoriasis. Treatment of hidradenitis suppurativa.

AU - Yao, Yiqiu

AU - Jørgensen , Astrid-Helene Ravn

AU - Nielsen, Valdemar Wendelboe

AU - Egeberg, Alexander

AU - Thyssen, Jacob Pontoppidan

AU - Thomsen, Simon Francis

PY - 2022

Y1 - 2022

M3 - Journal article

VL - 47

SP - 567

EP - 573

JO - Drugs of the Future

JF - Drugs of the Future

SN - 0377-8282

IS - 8

ER -